Loading stock data…
EW
$91.18+0.40 (+0.44%)
After Hours$90.49-0.69 (-0.76%)· Last close Jun 29
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Edwards Lifesciences Corporation in the Healthcare sector is trading at $91.18 with a market capitalization of $51.1B. Wall Street consensus targets $96.92 (26 analysts), implying a +6.3% move over the next 12 months. The stock is currently near its 52-week high of $92.88, remaining 10.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +6.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.65B↑ | $1.57B↑ | $1.55B↑ | $1.53B↑ | $1.41B |
| Gross Profit | $1.29B↑ | $1.23B↑ | $1.21B↑ | $1.19B↑ | $1.11B |
| Operating Income | $514.70M↑ | $370.30M↓ | $425.10M↓ | $430.90M↑ | $409.90M |
| Net Income | $380.70M↑ | $91.20M↓ | $291.10M↓ | $329.80M↓ | $358.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive re...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$51.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.58%
Volume
Today's trading volume
2.80M
Recent News
Can ISRG's 'Quintuple Aim' Strategy Continue to Justify Premium Pricing?
Intuitive Surgical's Quintuple Aim strategy is driving premium pricing as da Vinci 5 adoption grows, with innovation-led revenue growth outpacing procedure growth.
Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says
Edwards Lifesciences (EW) can sustain a high revenue growth rate given its technological leadership
Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic
Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.
Here's How Macro Trends and Currency Headwind Restrict GMED's Growth
Globus Medical faces inflation, geopolitical and currency pressures as rising costs and FX losses cloud margin flexibility and international growth.
Stocks Indexes Finish Mostly Lower as Chipmakers Retreat
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.57%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.89%. June E-mini S&P futures (ESM26 ) fell -0.60%, and June E-mini Nasdaq futures...